Neoplasm.News

Platinum agent × Thoracic × Clear all

5 Announcements

FDA approves amivantamab-vmjw with carboplatin and pemetrexed for non-small cell lung cancer with EGFR exon 19 deletions or L858R mutations

Trial: MARIPOSA-2
Drugs: Rybrevant (amivantamab-vmjw) · Anti-EGFR-HGFR bispecific antibody, carboplatin · Platinum agent, pemetrexed · Antifolate
Condition: Thoracic

FDA approves amivantamab-vmjw for EGFR exon 20 insertion-mutated non-small cell lung cancer indications

Trial: PAPILLON
Drugs: Rybrevant (amivantamab-vmjw) · Anti-EGFR-HGFR bispecific antibody, carboplatin · Platinum agent, pemetrexed · Antifolate
Condition: Thoracic

FDA approves atezolizumab with nab-paclitaxel and carboplatin for metastatic NSCLC without EGFR/ALK aberrations

Trial: IMpower130
Drugs: TECENTRIQ (atezolizumab) · Anti-PD-L1 antibody, paclitaxel protein-bound · Taxane, carboplatin · Platinum agent
Condition: Thoracic

FDA approves atezolizumab for extensive-stage small cell lung cancer

Trial: IMpower133
Drugs: TECENTRIQ (atezolizumab) · Anti-PD-L1 antibody, carboplatin · Platinum agent, etoposide · Topoisomerase II inhibitor
Condition: Thoracic

FDA approves pembrolizumab in combination with chemotherapy for first-line treatment of metastatic squamous NSCLC

Trial: KEYNOTE-407
Drugs: KEYTRUDA (pembrolizumab) · Anti-PD-1 antibody, carboplatin · Platinum agent
Condition: Thoracic